Search clinical trials for: Dasatinib plus anti-CD19/CD22 CAR-T cells

Total 480 results

Southwest Hospital, China

Unknown

the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
Hrain Biotechnology Co., Ltd.
Ruijin Hospital

Not yet recruiting

To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.

Acute Lymphoblastic Leukemia

China
Hrain Biotechnology Co., Ltd.
Second Affiliated Hospital of Nanchang University

Recruiting

Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients

Central Nervous System Lymphoma

China
Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma

B Cell Lymphoma | B Cell Leukemia

China
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.

Active, not recruiting

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

CAR

China
Beijing Tongren Hospital

Recruiting

CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia

B-cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
He Huang
Yake Biotechnology Ltd.

Recruiting

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients

CAR-T Cell | Ph Positive ALL | Dasatinib

China
Beijing GoBroad Hospital

Recruiting

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

Acute Lymphoblastic Leukemia, in Relapse | B-cell Acute Lymphoblastic Leukemia | Refractory Acute Lymphoid Leukemia

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Multiple Myeloma in Relapse | Multiple Myeloma, Refractory | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Acute Lymphocytic Leukaemia Refractory

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL

B-Cell Acute Lymphoblastic Leukemia, Adult

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
Hebei Senlang Biotechnology Inc., Ltd.
Tongji Hospital

Recruiting

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

19 and 22+ B Cell Hematologic Tumors | 19 and 20+ B Cell Hematologic Tumors

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL

B-Cell Acute Lymphoblastic Leukemia, Adult

China
Chongqing Precision Biotech Co., Ltd

Recruiting

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
University of Colorado, Denver

Recruiting

UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

Acute Lymphoblastic Leukemia | Acute Lymphoid Leukemia

United States
Chongqing Precision Biotech Co., Ltd

Recruiting

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL

B-ALL

China
Chongqing Precision Biotech Co., Ltd

Recruiting

a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

B Cell Lymphoma

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.; Chengdu Military...

Unknown

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

B Cell Lymphoma | B Cell Leukemia

China
Peking Union Medical College Hospital

Unknown

A Study of EXP039 Treatment in Subjects With r/r NHL Subjects

Non-Hodgkin's B-cell Lymphoma

China
Southwest Hospital, China

Unknown

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Lymphoma | Leukemia

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Lymphoma, B-Cell

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Withdrawn

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Refractory B Acute Lymphoblastic Leukemia | Relapse B Acute Lymphoblastic Leukemia

China
Affiliated Hospital to Academy of Military Medical...

Unknown

Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies

Lymphoma | Leukemia

China
Ruijin Hospital
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Unknown

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma

Lymphoma

China
Allife Medical Science and Technology Co., Ltd.
Peking University Cancer Hospital & Institute

Unknown

Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Refractory B-Cell Lymphoma
Miltenyi Biomedicine GmbH

Recruiting

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia Refractory

Germany
Fujian Medical University

Recruiting

Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma (A-02)

Relapsed or Refractory DLBCL Patients With Either CD19 or CD20 Positive

China
Miltenyi Biomedicine GmbH

Not yet recruiting

MB-CART19.1 in Refractory SLE

SLE - Systemic Lupus Erythematosus

Germany
First Affiliated Hospital of Zhejiang University

Unknown

An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection

Diffuse Large B Cell Lymphoma

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma,B Cell

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma,B Cell

China
Chimeric Therapeutics

Recruiting

CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Glioblastoma Multiforme of Brain

United States
Beijing Doing Biomedical Co., Ltd.

Not yet recruiting

Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

Lymphoma | Leukemia

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

Vasculitis | Amyloidosis | Autoimmune Hemolytic Anemia | POEMS Syndrome

China
First Affiliated Hospital of Wenzhou Medical University
Shanghai First Song Therapeutics Co., Ltd

Not yet recruiting

The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases

Systemic Sclerosis | Sjogren's Syndrome | Antiphospholipid Syndrome | ANCA Associated Vasculitis | Systemic Lupus Erythematosus (SLE) | Inflammatory Myopathy

China
KK Women's and Children's Hospital
Singapore General Hospital

Recruiting

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR | B-cell Acute Lymphoblastic Leukemia | Large B-cell Lymphoma

Singapore
The Children's Hospital of Zhejiang University...
Chongqing Precision Biotech Co., Ltd

Recruiting

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | CAR-T Cell Therapy

China
Southwest Hospital, China

Unknown

A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies

Lymphoma | Leukemia

China
Peking Union Medical College Hospital
Cellular Biomedicine Group Ltd.

Completed

A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

B-cell Non-Hodgkin Lymphoma

China
Seattle Children's Hospital

Active, not recruiting

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

CD 19+ Acute Leukemia

United States
Yan'an Affiliated Hospital of Kunming Medical University
KAEDI

Unknown

CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Miltenyi Biomedicine GmbH

Active, not recruiting

MB-CART20.1 Lymphoma

Non-Hodgkin's Lymphoma | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent

Germany
Miltenyi Biomedicine GmbH
DLR German Aerospace Center

Terminated

MB-CART20.1 Melanoma

Melanoma (Skin)

Germany
Zhejiang University
Shanghai YaKe Biotechnology Ltd.

Recruiting

CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases

Autoimmune Diseases

China
Zhejiang University
Shanghai YaKe Biotechnology Ltd.

Recruiting

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

Non-hodgkin Lymphoma,B Cell | Acute Lymphoblastic Leukemia,B-Cell

China
Liqun Zou

Recruiting

Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies

Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Leukemia

China
Yan'an Affiliated Hospital of Kunming Medical University

Recruiting

Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Essen Biotech

Not yet recruiting

Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). (BAH241)

Lymphoma, Follicular | Diffuse Large B Cell Lymphoma | Acute Lymphoblastic Leukemia, in Relapse | MCL | Central Nervous System Lymphoma | Acute Lymphoblastic Leukemia, Adult B-Cell | Non-Hodgkin Lymphoma, B-cell

China

Search clinical trials for: Dasatinib plus anti-CD19/CD22 CAR-T cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations